 JERSEY CITY, N.J., Aug. 02, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced grants of stock options to five new employees to purchase an aggregate of 24,500 shares of SCYNEXIS common stock at a per share exercise price of 6.97, the closing trading price on July 30, 2021. The stock options were granted as material inducements to the new employees to accept SCYNEXIS offers of employment. 